CA3141165A1 - Vaccine compositions for clostridium difficile - Google Patents

Vaccine compositions for clostridium difficile Download PDF

Info

Publication number
CA3141165A1
CA3141165A1 CA3141165A CA3141165A CA3141165A1 CA 3141165 A1 CA3141165 A1 CA 3141165A1 CA 3141165 A CA3141165 A CA 3141165A CA 3141165 A CA3141165 A CA 3141165A CA 3141165 A1 CA3141165 A1 CA 3141165A1
Authority
CA
Canada
Prior art keywords
seq
tcdb
holotoxin
immunogen
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141165A
Other languages
English (en)
French (fr)
Inventor
Rongsheng JIN
Philip Felgner
Peng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3141165A1 publication Critical patent/CA3141165A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3141165A 2019-05-21 2020-05-21 Vaccine compositions for clostridium difficile Pending CA3141165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851040P 2019-05-21 2019-05-21
US62/851,040 2019-05-21
PCT/US2020/034070 WO2020237090A1 (en) 2019-05-21 2020-05-21 Vaccine compositions for clostridium difficile

Publications (1)

Publication Number Publication Date
CA3141165A1 true CA3141165A1 (en) 2020-11-26

Family

ID=73458679

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141165A Pending CA3141165A1 (en) 2019-05-21 2020-05-21 Vaccine compositions for clostridium difficile

Country Status (8)

Country Link
US (1) US20220062401A1 (https=)
EP (1) EP3972638A4 (https=)
JP (1) JP7637988B2 (https=)
CN (1) CN114126644A (https=)
BR (1) BR112021023119A2 (https=)
CA (1) CA3141165A1 (https=)
MX (3) MX2021014097A (https=)
WO (1) WO2020237090A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4658302A1 (en) * 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
WO2013084071A2 (en) * 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2015123767A1 (en) * 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2019143552A1 (en) * 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling

Also Published As

Publication number Publication date
MX2026001280A (es) 2026-03-02
JP2022532917A (ja) 2022-07-20
MX2026001281A (es) 2026-03-02
EP3972638A4 (en) 2023-09-13
US20220062401A1 (en) 2022-03-03
EP3972638A1 (en) 2022-03-30
BR112021023119A2 (pt) 2022-01-25
WO2020237090A1 (en) 2020-11-26
CN114126644A (zh) 2022-03-01
JP7637988B2 (ja) 2025-03-03
MX2021014097A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
JP2022513798A (ja) トランスフェリン受容体標的ペプチド
US20230414748A1 (en) Scaffolded antigens and engineered sars-cov-2 receptor-binding domain (rbd) polypeptides
US8586081B2 (en) Detoxified recombinant botulinum neurotoxin
Islam et al. Analysis of amino acid contributions to protein solubility using short peptide tags fused to a simplified BPTI variant
US20240139332A1 (en) Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine Platforms
US20180371446A1 (en) Modified L-Asparaginase
Reed et al. Efficient sortase-mediated ligation using a common C-terminal fusion tag
Moyle et al. An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system
US20220062401A1 (en) Vaccine compositions for clostridium difficile
WO2013087857A2 (de) Antikörper gegen toxine von c. difficile
WO2013087874A1 (de) Antikörper gegen das cdt-toxin von c. difficile
IL285452B2 (en) A new recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
BRPI0714380A2 (pt) composiÇÕes anticocaÍna e tratamento
US20230287402A1 (en) Two component co-assembling two dimensional protein structures
Burkhardt et al. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A
Craig et al. Multiple display of a protein domain on a bacterial polymeric scaffold
US20200405836A1 (en) Epsilon toxin from clostridium perfringens as a vaccine
US20160106819A1 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
Luchansky et al. Amino acid transport in thermophiles: characterization of an arginine-binding protein in Thermotoga maritima
Goodin et al. Yersinia pestis outer membrane type III secretion protein YscC: expression, purification, characterization, and induction of specific antiserum
Romano Chernac Structural Studies of Membrane-Assembled PopD and PopB, the Pseudomonas aeruginosa Type 3 Secretion Translocators
US10188716B2 (en) Protective antigen complexes with increased stability and uses thereof
Leka Structural and functional characterization of AB toxins: diphtheria toxin and clostridial neurotoxins
Mitchell Peptide-Based Inhibitors of Bacterial Small Multidrug Resistance Proteins
Perrotta Advancing technology platforms for the development of bacterial vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240923

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250516

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250516

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250516

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250516

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260106

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106